Results 241 to 250 of about 209,966 (285)
Some of the next articles are maybe not open access.
Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Immunology and Allergy Clinics of North America, 2023Idiopathic pulmonary fibrosis (IPF), a common interstitial lung disease (ILD), is a chronic, progressive fibrosing interstitial pneumonia, with an unknown cause. IPF has been linked to several genetic and environmental risk factors. Disease progression is common and associated with worse outcomes.
Rachel, Strykowski, Ayodeji, Adegunsoye
openaire +2 more sources
BMJ, 2013
Idiopathic pulmonary fibrosis (IPF) is a steadily progressive and ultimately fatal disease of unknown origin. Recent years have seen advances in our understanding of IPF and a number of guidelines have been published. But many questions remain unanswered, particularly surrounding probable versus definite IPF.
Owen J, Dempsey, David, Miller
openaire +3 more sources
Idiopathic pulmonary fibrosis (IPF) is a steadily progressive and ultimately fatal disease of unknown origin. Recent years have seen advances in our understanding of IPF and a number of guidelines have been published. But many questions remain unanswered, particularly surrounding probable versus definite IPF.
Owen J, Dempsey, David, Miller
openaire +3 more sources
New England Journal of Medicine, 2001
Idiopathic pulmonary fibrosis is a rapidly progressive illness of unknown cause characterized by sequential acute lung injury with subsequent scarring and end-stage lung disease. Treatment at present remains largely supportive, with evidence that patients' satisfaction and survival may be improved by referral to centers specializing in the evaluation ...
T J, Gross, G W, Hunninghake
openaire +3 more sources
Idiopathic pulmonary fibrosis is a rapidly progressive illness of unknown cause characterized by sequential acute lung injury with subsequent scarring and end-stage lung disease. Treatment at present remains largely supportive, with evidence that patients' satisfaction and survival may be improved by referral to centers specializing in the evaluation ...
T J, Gross, G W, Hunninghake
openaire +3 more sources
Respirology (Carlton South. Print), 2022
There remains a paucity of large databases for patients with idiopathic pulmonary fibrosis (IPF) and lung cancer. We aimed to create a European registry.
T. Karampitsakos +29 more
semanticscholar +1 more source
There remains a paucity of large databases for patients with idiopathic pulmonary fibrosis (IPF) and lung cancer. We aimed to create a European registry.
T. Karampitsakos +29 more
semanticscholar +1 more source
Clinics in Chest Medicine, 1982
SUMMARY Idiopathic pulmonary fibrosis is a precise syndrome defined by clinical, roentgenographic, physiologic, and histopathologic features. Clinically, most patients have a nonproductive cough and dyspnea on exertion. The most common physical finding is the presence of crackles over the lower portions of both lungs; also, there may be clubbing ...
openaire +2 more sources
SUMMARY Idiopathic pulmonary fibrosis is a precise syndrome defined by clinical, roentgenographic, physiologic, and histopathologic features. Clinically, most patients have a nonproductive cough and dyspnea on exertion. The most common physical finding is the presence of crackles over the lower portions of both lungs; also, there may be clubbing ...
openaire +2 more sources
Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis
Chest, 2007Idiopathic pulmonary fibrosis (IPF) is an untreatable diffuse parenchymal lung disease with a median survival of < 3 years. Pulmonary hypertension (PH) is frequently seen in patients with IPF and is commonly attributed to hypoxic vasoconstriction and capillary destruction. Pathology findings include endothelial proliferation and medial hypertrophy that
Nina M, Patel +3 more
openaire +2 more sources
Annual Review of Medicine, 1993
Idiopathic pulmonary fibrosis kills half of its victims within five years of diagnosis. Currently available treatment regimens are disappointing, and the incidence of the disease appears to be increasing. Newer techniques of imaging coupled with laboratory advances in molecular and cellular biology may produce new strategies for modulating the disease ...
openaire +2 more sources
Idiopathic pulmonary fibrosis kills half of its victims within five years of diagnosis. Currently available treatment regimens are disappointing, and the incidence of the disease appears to be increasing. Newer techniques of imaging coupled with laboratory advances in molecular and cellular biology may produce new strategies for modulating the disease ...
openaire +2 more sources
Current Opinion in Pulmonary Medicine, 1996
Idiopathic pulmonary fibrosis (IPF), or cryptogenic fibrosing alveolitis as it is known in the United Kingdom and Europe, is perhaps one of the most complex and frustrating pulmonary disorders. The cause of this illness is unknown. Treatment often founders in a mire of discontent, dissatisfaction, and failure. In fact, the philosophic homily "If you do
openaire +2 more sources
Idiopathic pulmonary fibrosis (IPF), or cryptogenic fibrosing alveolitis as it is known in the United Kingdom and Europe, is perhaps one of the most complex and frustrating pulmonary disorders. The cause of this illness is unknown. Treatment often founders in a mire of discontent, dissatisfaction, and failure. In fact, the philosophic homily "If you do
openaire +2 more sources
Familial Idiopathic Pulmonary Fibrosis
2013Idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease of unknown etiology, with an appearance of usual interstitial pneumonia on lung biopsy. To-date, about a 100 families diagnosed with IPF have been described. Familial IPF is defined as histologically confirmed IPF occurring in two or more members of a family.
K, Wytrychowski +2 more
openaire +2 more sources
[Idiopathic pulmonary fibrosis].
Presse medicale (Paris, France : 1983), 2006Idiopathic pulmonary fibrosis is a chronic disorder characterized histopathologically by a pattern of usual interstitial pneumonia, with heterogeneous and mutilating interstitial fibrosis with foci of proliferating fibroblasts, honeycomb lung, and little if any inflammation.
Cottin, Vincent, Cordier, Jean-François
openaire +3 more sources